ATE298334T1 - Kristalle von lansoprazole - Google Patents

Kristalle von lansoprazole

Info

Publication number
ATE298334T1
ATE298334T1 AT00942388T AT00942388T ATE298334T1 AT E298334 T1 ATE298334 T1 AT E298334T1 AT 00942388 T AT00942388 T AT 00942388T AT 00942388 T AT00942388 T AT 00942388T AT E298334 T1 ATE298334 T1 AT E298334T1
Authority
AT
Austria
Prior art keywords
crystals
lansoprazole
pyridinylümethylüsulfinyl
2äää3
trifluoroethoxy
Prior art date
Application number
AT00942388T
Other languages
English (en)
Inventor
Akira Fujishima
Isao Aoki
Keiji Kamiyama
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Application granted granted Critical
Publication of ATE298334T1 publication Critical patent/ATE298334T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Dental Preparations (AREA)
AT00942388T 1999-06-30 2000-06-29 Kristalle von lansoprazole ATE298334T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP18640399 1999-06-30
PCT/JP2000/004279 WO2001002389A1 (fr) 1999-06-30 2000-06-29 Cristaux de composes benzimidazole

Publications (1)

Publication Number Publication Date
ATE298334T1 true ATE298334T1 (de) 2005-07-15

Family

ID=16187808

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00942388T ATE298334T1 (de) 1999-06-30 2000-06-29 Kristalle von lansoprazole

Country Status (9)

Country Link
US (4) US6608092B1 (de)
EP (1) EP1191025B1 (de)
AT (1) ATE298334T1 (de)
AU (1) AU5705700A (de)
CA (1) CA2375091A1 (de)
DE (1) DE60020967T2 (de)
ES (1) ES2240113T3 (de)
PT (1) PT1191025E (de)
WO (1) WO2001002389A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US20040224989A1 (en) * 1999-01-29 2004-11-11 Barberich Timothy J. S-lansoprazole compositions and methods
TWI289557B (en) * 1999-06-17 2007-11-11 Takeda Chemical Industries Ltd A crystal of a hydrate of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
EP1191025B1 (de) * 1999-06-30 2005-06-22 Takeda Pharmaceutical Company Limited Kristalle von lansoprazole
DE60016617T2 (de) * 1999-10-01 2005-04-28 Natco Pharma Ltd., Banjara Hills Magensaftresistente gelartige weichkapsel
ES2273829T3 (es) 2000-04-28 2007-05-16 Takeda Pharmaceutical Company Limited Procedimiento para producir derivado de sulfoxido opticamente activo.
ES2293988T3 (es) * 2000-05-15 2008-04-01 Takeda Pharmaceutical Company Limited Procedimiento para producir un cristal.
JP5412023B2 (ja) * 2000-08-04 2014-02-12 武田薬品工業株式会社 ベンズイミダゾール化合物の塩およびその用途
HU229356B1 (en) * 2000-12-01 2013-11-28 Takeda Pharmaceutical Process for the crystallization of (r)- or (s)-lansoprazole
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
US6897208B2 (en) 2001-10-26 2005-05-24 Aventis Pharmaceuticals Inc. Benzimidazoles
CN1681802A (zh) * 2002-03-27 2005-10-12 特瓦制药工业有限公司 兰索拉唑多晶型和其制备方法
CA2502219C (en) 2002-10-16 2012-05-29 Takeda Pharmaceutical Company Limited A process for producing an amorphous isomer of lansoprazole
US20050220870A1 (en) * 2003-02-20 2005-10-06 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
EP1648417A4 (de) * 2003-07-18 2010-01-20 Santarus Inc Pharmazeutische formulierung und verfahren zur behandlung von säurebedingten gastrointestinalen erkrankungen
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
TWI398273B (zh) * 2003-07-18 2013-06-11 Santarus Inc 用於抑制酸分泌之醫藥調配物及其製備及使用之方法
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
WO2005076987A2 (en) * 2004-02-10 2005-08-25 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent
US20050239845A1 (en) * 2004-04-16 2005-10-27 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and prokinetic agent
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US9101160B2 (en) 2005-11-23 2015-08-11 The Coca-Cola Company Condiments with high-potency sweetener
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
US8017168B2 (en) 2006-11-02 2011-09-13 The Coca-Cola Company High-potency sweetener composition with rubisco protein, rubiscolin, rubiscolin derivatives, ace inhibitory peptides, and combinations thereof, and compositions sweetened therewith
KR101321055B1 (ko) * 2008-11-14 2013-10-23 한미사이언스 주식회사 덱스란소프라졸의 신규 결정형 및 이를 포함하는 약학 조성물
CN104997739A (zh) * 2015-08-31 2015-10-28 青岛蓝盛洋医药生物科技有限责任公司 一种治疗消化系统疾病的药物兰索拉唑组合物冻干粉针剂

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
DK171989B1 (da) * 1987-08-04 1997-09-08 Takeda Chemical Industries Ltd Fremgangsmåde til fremstilling af 2-(2-pyridylmethylsulfinyl)-benzimidazoler
DE4035455A1 (de) * 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
SE504459C2 (sv) 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
GB9423968D0 (en) 1994-11-28 1995-01-11 Astra Ab Resolution
HRP960232A2 (en) 1995-07-03 1998-02-28 Astra Ab A process for the optical purification of compounds
TW385306B (en) 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
JP3260389B2 (ja) 1998-01-23 2002-02-25 仗祐 中田 光電解装置用太陽電池モジュール及び光電解装置
WO1999038512A1 (en) * 1998-01-30 1999-08-05 Sepracor Inc. S-lansoprazole compositions and methods
AU3596199A (en) 1998-05-06 1999-11-23 Kobenhavns Universitet Treatment of celiac disease
TWI289557B (en) * 1999-06-17 2007-11-11 Takeda Chemical Industries Ltd A crystal of a hydrate of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
EP1191025B1 (de) * 1999-06-30 2005-06-22 Takeda Pharmaceutical Company Limited Kristalle von lansoprazole

Also Published As

Publication number Publication date
CA2375091A1 (en) 2001-01-11
PT1191025E (pt) 2005-09-30
EP1191025A4 (de) 2003-07-09
US20070155796A1 (en) 2007-07-05
DE60020967T2 (de) 2006-05-04
WO2001002389A1 (fr) 2001-01-11
DE60020967D1 (de) 2005-07-28
US20040082791A1 (en) 2004-04-29
US7189744B2 (en) 2007-03-13
AU5705700A (en) 2001-01-22
EP1191025A1 (de) 2002-03-27
ES2240113T3 (es) 2005-10-16
EP1191025B1 (de) 2005-06-22
US20050171162A1 (en) 2005-08-04
US6903122B2 (en) 2005-06-07
US6608092B1 (en) 2003-08-19

Similar Documents

Publication Publication Date Title
DE60020967D1 (de) Kristalle von lansoprazole
NO20016087D0 (no) Benzimidazolforbindelsekrystall
DE60123800D1 (de) Salze von benzimidazol-derivaten und deren verwendung
NO921609D0 (no) Sulfonamider og deres medisinske anvendelse
ATE182145T1 (de) Optisch aktive pyridoncarbonsäure-derivate
FI903331A0 (fi) Substituerade kinazolinoner, vilka aer anvaendbara som angiotensin-ii-antagonister.
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
BR0014352A (pt) Cetoenóis espirocìclicos substituìdos por trifluormetila
SE9702483L (sv) Termodynamiskt stabil omeprazol natrium form B
FI93831B (fi) Tetratsolit, jotka ovat verenpainetta alentavien yhdisteiden välituotteita
DE69925256D1 (de) Trisubstituierte 1,3,5-triazine derivate zur behandlung von hiv infektionen
DK0842934T3 (da) 5-HT1F agonister
DK506587A (da) Imidderivater
FI974441A0 (fi) Vedettömän 7-(/1alfa,5alfa,6alfa/-6-amino-3-atsabisyklo(3.1.0)heks-3-yyli)-6-fluori-1-(2,4-difluorifenyyli)-1,4-dihydro-4-okso,1,8-naftyridiini-3-karboksyylihapon metaanisulfonihapposuolan uusi kidemuoto
ATE248822T1 (de) Partikel mit kontrollierter freisetzungsrate
ATE250021T1 (de) Hydroxycyclopentanone
NO930205D0 (no) Benzimidazoler, legemidler inneholdende disse, og fremgangsmaate for deres fremstilling
ATE289606T1 (de) Kristallmodifikation b von 8-cyan- 1-cyclopropyl -7-(1s,6s-2, 8-diazabicyclo - 4.3.0)nonan -8-yl)-6-fluor-1, 4-dihydro- 4-oxo-3- chinolincarbonsaure
ATE240326T1 (de) Pyrrolo-(3,2-b)pyridine und ihre verwendung als 5-ht1f agonisten
DK162839C (da) N,3-diacyl-2-oxindol-1-carboxamid-forbindelser og 3-acyl-2-oxindol-forbindelser til anvendelse som mellemprodukter ved deres fremstilling
TH69761B (th) ผลึกสารประกอบเบนซิมิแดซอล
DE69815347D1 (de) Tetrahydrofuranderivate
FR2803316B1 (fr) Cordeau d'alignement notamment pour la maconnerie
ECSP003736A (es) Procedimiento mejorado para la preparacion de derivados de bencimidazol adecuados como farmacos antiulcerosos, particularmente omeprazol o pantoprazol
UY26420A1 (es) Procedimiento mejorado para la preparación de derivados bencimidazol adecuados como fármacos antiulcerosos, particularmente omeprazol o pantoprazol

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1191025

Country of ref document: EP

REN Ceased due to non-payment of the annual fee